© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to May
CDC7 serine/threonine kinase inhibitor
oral 50 mg QD, Ph. II in solid tumors compl.
from homology model pharmacophore + opt.
Sci. Adv., May 21, 2021
Takeda Pharmaceutical, Kanagawa, JP
The Takeda CDC7 serine/threonine kinase inhibitor, simurosertib (TAK-931), is the first orally active CDC7-selective inhibitor and recently had its Ph. I study results in solid tumors posted. The drug was…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.